Karius

Karius is a biotechnology company that specializes in advanced genomic diagnostics for infectious diseases. The company focuses on improving pathogen detection through clinical metagenomics and artificial intelligence, aiming to provide rapid and non-invasive diagnostic solutions. Karius is dedicated to delivering timely and accurate diagnoses, particularly for immunocompromised patients and those with life-threatening infections. The Karius Test™ is a liquid biopsy that detects microbial cell-free DNA from over 1,000 pathogens using a single blood sample. This non-invasive method offers a faster and more comprehensive alternative to traditional culture-based diagnostics. The Karius Spectrum™ enhances this approach with a focus on rapid turnaround and high accuracy for critical care settings. Karius employs proprietary AI-driven analysis to interpret genomic data, identifying pathogens and their resistance profiles effectively. Karius operates a CLIA-certified laboratory and is backed by significant funding to expand access to its diagnostics. The company primarily serves hospitals and healthcare providers, aiming to reduce diagnostic delays and combat antimicrobial resistance through targeted therapies.